DE602004029393D1 - Tgf-beta1-bindende und geträgerte peptide - Google Patents

Tgf-beta1-bindende und geträgerte peptide

Info

Publication number
DE602004029393D1
DE602004029393D1 DE602004029393T DE602004029393T DE602004029393D1 DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1 DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1
Authority
DE
Germany
Prior art keywords
peptides
supported
tgf
preferred embodiments
supported peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029393T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of DE602004029393D1 publication Critical patent/DE602004029393D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
DE602004029393T 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide Expired - Lifetime DE602004029393D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53095403P 2003-12-19 2003-12-19
US53120703P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
PCT/US2004/036979 WO2005046710A2 (en) 2003-11-06 2004-11-06 Tgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
DE602004029393D1 true DE602004029393D1 (de) 2010-11-11

Family

ID=34596198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004029812T Expired - Lifetime DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
DE602004029393T Expired - Lifetime DE602004029393D1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602004029812T Expired - Lifetime DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692159B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE482972T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029812D1 (de)
DK (2) DK1692158T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005046710A2 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006246425B2 (en) * 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
CA2544820C (en) * 2003-11-06 2014-02-18 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
JP5255841B2 (ja) * 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
JP4989638B2 (ja) * 2005-06-10 2012-08-01 メディカル リサーチ カウンシル 足場
TW200745159A (en) * 2005-07-13 2007-12-16 Avidia Inc IL-6 binding proteins
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
PL2061313T3 (pl) * 2006-09-16 2014-01-31 Soy Labs Llc Zastosowanie peptydu sojowego (lunazyny) do obniżania poziomu cholesterolu całkowitego i ldl
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
ES2386991T3 (es) 2006-12-18 2012-09-10 Danisco Us Inc. Nuevas composiciones de laccasas y sus procedimientos de utilización
BRPI0722093A2 (pt) * 2006-12-21 2014-04-01 Danisco Us Inc Genencor Div Composições e usos para um polipeptídeo de alfa-amilase da espécie bacillus 195
BRPI0812448A2 (pt) * 2007-06-06 2014-10-14 Danisco Us Inc Genecor Division Método para aperfeiçoamento de propriedades de proteína
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
WO2009058518A1 (en) * 2007-10-31 2009-05-07 Danisco Us Inc., Genencor Division Use and production of neutral metallproteases in a serine protease-free background
US20090221030A1 (en) * 2007-11-01 2009-09-03 Kai Bao Signal sequences and co-expressed chaperones for improving protein production in a host cell
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
AU2008349567A1 (en) * 2008-01-29 2009-08-06 Danisco Us Inc. Expression of streptomyces subtilisin inhibitor (SSI) proteins in bacillus and streptomyces sp.
CA2713582C (en) 2008-02-04 2017-02-21 Danisco Us Inc. Ts23 alpha-amylase variants with altered properties
RU2509776C2 (ru) * 2008-10-15 2014-03-20 ДАНИСКО ЮЭс ИНК. МОДИФИЦИРОВАННЫЕ ВАРИАНТЫ ИНГИБИТОРОВ ПРОТЕАЗ Bowman Birk
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20120172275A1 (en) 2009-03-10 2012-07-05 Danisco Us Inc. Bacillus Megaterium Strain DSM90-Related Alpha-Amylases, and Methods of Use, Thereof
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
US8877479B2 (en) 2009-04-08 2014-11-04 Danisco Us Inc. Halomonas strain WDG195-related alpha-amylases, and methods of use, thereof
WO2010123754A1 (en) 2009-04-24 2010-10-28 Danisco Us Inc. Proteases with modified pro regions
CA2760554A1 (en) * 2009-05-01 2010-11-04 Signal Investment And Management Co. Moisturizing antimicrobial composition
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
EP2478003A4 (de) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr4-domänen
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
JP5863666B2 (ja) 2009-12-09 2016-02-17 ダニスコ・ユーエス・インク プロテアーゼ変異体を含む組成物及び方法
EP2512501A4 (de) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen
EP2519251A4 (de) * 2009-12-30 2013-08-28 Solae Llc Aus einem sojaverarbeitungsstrom isolierte gereinigte bowman-birk-protease-hemmerproteine
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
US9067084B2 (en) * 2010-03-31 2015-06-30 Agency For Science, Technology And Research Amphiphilic linear peptide/peptoid and hydrogel comprising the same
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
EP2558573B1 (de) 2010-04-15 2017-02-22 Danisco US Inc. Zusammensetzungen und verfahren mit proteasevarianten
PL3575389T3 (pl) 2010-05-06 2025-06-02 The Procter & Gamble Company Produkty konsumenckie z odmianami proteaz
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
MX357386B (es) 2011-05-05 2018-07-06 Procter & Gamble Composiciones y metodos que comprenden variantes de proteasa serina.
MX378782B (es) 2011-05-05 2025-03-10 Danisco Us Inc Composiciones y metodos que comprenden variantes de proteasa serina.
EP2751263A1 (de) 2011-08-31 2014-07-09 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
CN104024407A (zh) 2011-12-22 2014-09-03 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
CN110093330B (zh) 2012-10-12 2023-11-28 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
AU2013337255A1 (en) 2012-11-05 2015-04-02 Danisco Us Inc. Compositions and methods comprising thermolysin protease variants
EP2935573A1 (de) 2012-12-19 2015-10-28 Danisco US Inc. Neuartige mannase, zusammensetzungen und verfahren zur verwendung davon
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3004341B1 (de) 2013-05-29 2017-08-30 Danisco US Inc. Neuartige metalloproteasen
EP3636662B1 (de) 2013-05-29 2022-07-13 Danisco US Inc. Neuartige metalloproteasen
WO2014194032A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3696264B1 (de) 2013-07-19 2023-06-28 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
US20160222368A1 (en) 2013-09-12 2016-08-04 Danisco Us Inc. Compositions and Methods Comprising LG12-CLADE Protease Variants
EP3055328A1 (de) * 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Nsp4-hemmer und verfahren zur verwendung
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
CN106029881B (zh) 2013-12-13 2023-01-10 丹尼斯科美国公司 吉氏芽孢杆菌-进化枝的丝氨酸蛋白酶
DK3080262T3 (da) 2013-12-13 2019-05-06 Danisco Us Inc Serinproteaser af bacillus-arter
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
JP6585698B2 (ja) 2014-03-21 2019-10-02 ダニスコ・ユーエス・インク バチルス（Ｂａｃｉｌｌｕｓ）種のセリンプロテアーゼ
EP3207129B1 (de) 2014-10-17 2019-11-20 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
EP3212783B1 (de) 2014-10-27 2024-06-26 Danisco US Inc. Serinproteasen
DK3212662T3 (da) 2014-10-27 2020-07-20 Danisco Us Inc Serinproteaser
EP3212782B1 (de) 2014-10-27 2019-04-17 Danisco US Inc. Serinproteasen
DK3212781T3 (da) 2014-10-27 2019-12-16 Danisco Us Inc Serinproteaser
US20180010074A1 (en) 2014-10-27 2018-01-11 Danisco Us Inc. Serine proteases of bacillus species
WO2016145428A1 (en) 2015-03-12 2016-09-15 Danisco Us Inc Compositions and methods comprising lg12-clade protease variants
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3872174B1 (de) 2015-05-13 2023-03-01 Danisco US Inc. Aprl-clade-protease-varianten and verwendungen davon
CA2989667A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
WO2016205755A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
US20190136218A1 (en) 2016-05-05 2019-05-09 Danisco Us Inc Protease variants and uses thereof
CN109477112B (zh) 2016-05-31 2024-09-06 丹尼斯科美国公司 蛋白酶变体及其用途
CA3027745A1 (en) 2016-06-17 2017-12-21 Danisco Us Inc. Protease variants and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4520820A3 (de) 2016-12-21 2025-04-16 Danisco Us Inc Proteasevarianten und verwendungen davon
CN110312794B (zh) 2016-12-21 2024-04-12 丹尼斯科美国公司 吉氏芽孢杆菌进化枝丝氨酸蛋白酶
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
EP3717643A1 (de) 2017-11-29 2020-10-07 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3833731A1 (de) 2018-08-30 2021-06-16 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
EP3875591A4 (de) * 2018-10-31 2022-09-21 Qingdao Vland Biotech Group Co. Ltd. Verfahren zur herstellung eines waschenzyms mit proteaseresistenz
EP3887515A1 (de) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
CN114174504B (zh) 2019-05-24 2026-04-17 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2021146255A1 (en) 2020-01-13 2021-07-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
EP3872088A1 (de) * 2020-02-28 2021-09-01 Alganelle Verwendung von aprotinin als träger zum herstellen eines rekombinanten proteins, polypeptides oder peptids in algen
US20240034960A1 (en) 2020-08-27 2024-02-01 Danisco Us Inc Enzymes and enzyme compositions for cleaning
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
EP4448712A1 (de) 2021-12-16 2024-10-23 The Procter & Gamble Company Protease enthaltende zusammensetzung für geschirrspülmaschinen
US20230365897A1 (en) 2021-12-16 2023-11-16 The Procter & Gamble Company Fabric and home care composition including a protease
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
EP4448751A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
US20260078362A1 (en) 2022-09-02 2026-03-19 Danisco Us Inc. Subtilisin variants and methods related thereto
JP2025530749A (ja) 2022-09-02 2025-09-17 ダニスコ・ユーエス・インク 洗剤組成物及びそれに関連する方法
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use
WO2024163584A1 (en) 2023-02-01 2024-08-08 Danisco Us Inc. Subtilisin variants and methods of use
EP4410941A1 (de) 2023-02-01 2024-08-07 The Procter & Gamble Company Enzymhaltige waschmittelzusammensetzungen
CN120712348A (zh) 2023-03-06 2025-09-26 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN121909283A (zh) 2023-09-28 2026-04-21 丹尼斯科美国公司 具有改善的溶解度的变体角质酶及其用途
WO2025085351A1 (en) 2023-10-20 2025-04-24 Danisco Us Inc. Subtilisin variants and methods of use
WO2026024922A1 (en) 2024-07-25 2026-01-29 Danisco Us Inc. Subtilisin variants and methods of use
WO2026050315A1 (en) 2024-08-29 2026-03-05 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3929678A (en) * 1974-08-01 1975-12-30 Procter & Gamble Detergent composition having enhanced particulate soil removal performance
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
CA2206048C (en) 1994-11-28 2002-03-19 Darrell Gene Doughty Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
AU5713896A (en) * 1996-03-12 1997-10-01 Genencor International, Inc. Alkaline cellulase and method of producing same
EP0991422A1 (de) * 1996-04-18 2000-04-12 The General Hospital Corporation Modulierende interaktionen des epitheliums und des mesenchyms
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
KR20000057166A (ko) 1996-11-22 2000-09-15 데이비드 엠 모이어 미용 조성물
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
ATE223971T1 (de) * 1998-07-20 2002-09-15 Inoxell As Neue methoden zum auffinden von liganden- und ziel-biomolekülen
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
ES2338097T3 (es) * 2000-04-14 2010-05-04 Genencor International, Inc. Procedimiento de identificacion selectiva.
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002621A2 (en) * 2000-06-30 2002-01-10 Zymogenetics, Inc. Mammalian secreted proteins
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
ATE431851T1 (de) * 2000-12-13 2009-06-15 Anaphore Inc Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c- typ lectin-ähnlichen domäne als gerüststruktur
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20070020625A1 (en) * 2001-02-07 2007-01-25 Eric Duchaud Sequence of the photorhabdus luminescens strain tt01 genome and uses
EP1592788A2 (de) * 2003-02-11 2005-11-09 Institut Pasteur Identifizierung und charakterisierung von racemasen, definition von protein-signaturen und tests für die identifizierung von d-aminosäuren und zum screenen von molekülen, die die aktivität von racemasen, insbesondere prolin-racemasen inhibieren
CA2544820C (en) * 2003-11-06 2014-02-18 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors

Also Published As

Publication number Publication date
WO2005046709A2 (en) 2005-05-26
EP1692160A2 (de) 2006-08-23
EP1692159B1 (de) 2010-09-29
ES2375360T3 (es) 2012-02-29
US20080113917A1 (en) 2008-05-15
ATE530560T1 (de) 2011-11-15
EP1692158B1 (de) 2011-10-26
US20090111160A1 (en) 2009-04-30
JP5728329B2 (ja) 2015-06-03
DE602004029812D1 (de) 2010-12-09
US7696173B2 (en) 2010-04-13
US20080269139A1 (en) 2008-10-30
ATE482972T1 (de) 2010-10-15
WO2005046709A3 (en) 2005-11-24
ATE486087T1 (de) 2010-11-15
JP2008500805A (ja) 2008-01-17
WO2005047511A2 (en) 2005-05-26
US20050203026A1 (en) 2005-09-15
CA2544820C (en) 2014-02-18
US7413877B2 (en) 2008-08-19
WO2005047511A3 (en) 2005-11-24
WO2005046710A2 (en) 2005-05-26
US7524816B2 (en) 2009-04-28
DK1680507T3 (da) 2011-10-10
CA2544820A1 (en) 2005-05-26
EP1692158A2 (de) 2006-08-23
WO2005047314A2 (en) 2005-05-26
WO2005047314A3 (en) 2006-04-20
WO2005046710A3 (en) 2005-11-24
EP1692160B1 (de) 2010-10-27
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
US20110230405A1 (en) 2011-09-22
US20050238607A1 (en) 2005-10-27
JP2012024091A (ja) 2012-02-09
US20050202535A1 (en) 2005-09-15
EP1692159A2 (de) 2006-08-23
US7485618B2 (en) 2009-02-03
ATE513917T1 (de) 2011-07-15
JP4843497B2 (ja) 2011-12-21
US20130065829A1 (en) 2013-03-14
EP1680507A2 (de) 2006-07-19

Similar Documents

Publication Publication Date Title
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE602004011770D1 (de) Fusionsproteine
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DE602004019965D1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DK1534830T3 (da) In vito-peptid-ekspressionsbibliotek
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
NO20074374L (no) Fremgangsmate for fremstilling av polypeptidblandinger ved anvendelse av hydrogenolyse
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
ATE363531T1 (de) Claudin polypeptide
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
HRP20050024A2 (en) Pegylated t20 polypeptide
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DK1387854T3 (da) SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf